Cardiac risk in the treatment of breast cancer: assessment and management

Antonis Valachis¹
Cecilia Nilsson²

¹Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; ²Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden

Abstract: As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities.

Keywords: adjuvant, anthracyclines, cardiac toxicity, radiotherapy, trastuzumab

Introduction
Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. The advances in the diagnosis and treatment of breast cancer have led to an improved outcome and a large proportion of long-term breast cancer survivors. It is estimated that nearly 90% of women diagnosed with breast cancer will survive for 5 years or longer.

The cornerstone of breast cancer therapy is surgery. It is well documented that many patients with early breast cancer benefit from postoperative adjuvant therapy (radiotherapy, chemotherapy, targeted therapy, or endocrine therapy), a treatment strategy with a view to eradicate distant micrometastatic deposits. The choice of appropriate adjuvant therapy is based on the stage of the disease, the functional status and comorbid condition of the patient, and the clinicopathological and molecular characteristics of the tumor. Several adjuvant therapies against breast cancer can potentially cause a wide range of acute and late cardiac complications. This subject is of rising concern considering the increased number of long-term breast cancer survivors and the trend to combine two or more potentially cardiotoxic therapies in the adjuvant setting.

The goal of this review is to summarize the current knowledge on the incidence of cardiac toxicity in different adjuvant breast cancer therapies and highlight the current trends in early detection and management of cardiac toxicities. This review is focused on well-established and widely used adjuvant therapies (radiotherapy, chemotherapy, anti-human epidermal growth factor 2 (anti-HER2) therapy) and not on experimental therapies.

Radiotherapy-induced cardiac toxicity in early breast cancer
Adjuvant radiotherapy is recommended in most of the patients undergoing breast cancer surgery. Adjuvant whole breast radiotherapy after breast-conserving surgery...
reduces the risk of local recurrences by about two-thirds. In cases of mastectomy, radiotherapy is recommended for all patients with node-positive disease, and in T3–T4 disease radiotherapy is recommended irrespective of nodal status. In node-positive patients, radiotherapy reduces the risk of breast cancer mortality and increases overall survival; for these patients, approximately one breast cancer death is avoided for every 1.5 recurrences of any type after radiotherapy.

However, a major concern when radiotherapy is administered in patients with early breast cancer with an expected long-term survival is the unintentional irradiation of adjacent organs. Several studies demonstrate an excess of cardiac deaths after longer follow-up that partly counterbalance the decrease in breast cancer death.

The underlying pathophysiological mechanisms of radiation-induced heart disease (RIHD) are related to micro- and macrovascular damage, which leads to clinical manifestations such as pericarditis, coronary artery disease, acute myocardial infarction, valvular heart disease, and cardiomyopathy. Most data regarding the risk of cardiac morbidity and mortality subsequent to radiotherapy comes from retrospective population-based studies that have compared cardiac outcome after left- versus right-sided breast irradiation. In an analysis from the US Surveillance, Epidemiology, and End Results (SEER) database that includes patients treated during the period 1973–2001, a significantly increased risk of cardiac mortality was seen after left-side irradiation. Similar results have been seen in two other studies that included patients during the periods 1954–1984 and 1977–1994. In all of these studies which entail long time periods, a non-negligible portion of patients were treated with older radiotherapy techniques, which were often associated with high mean radiation doses to the heart. The cardiac side effects of contemporary radiotherapy are less investigated since a long follow-up is essential to reveal clinically significant RIHD. Nonetheless, in the above-mentioned SEER analysis, different time periods were compared and the results indicated a reduction in cardiac morbidity during the latest time period when more modern radiation techniques were implemented.

This decrease in cardiac morbidity according to time period could also reflect an increased knowledge about important parameters in breast radiotherapy, such as the mean radiation dose. Recently, Darby et al demonstrated that the risk of major coronary events increased linearly with the mean radiation dose to the entire heart. This increased risk was observed as soon as 5 years after radiotherapy had been completed and continued for 3 decades. Similarly, studies have investigated cardiac radiation doses in left-side breast or chest wall irradiation during different time periods and have revealed a considerable decrease in whole heart doses over the past decades.

In some recent guidelines, the entire heart is considered as an organ at risk with defined radiation dose limits. Nevertheless, the heart consists of different structures, probably with different levels of radiation tolerance. Furthermore, the dose distribution in the heart during tangential whole breast radiotherapy is inhomogeneous, with higher doses delivered to the anterior part of the heart. Nilsson et al demonstrated a four- to sevenfold increased risk of stenosis in coronary arteries in areas with hot spot radiation doses; the increased risk was observed mainly to the left anterior descending artery (LAD). Similarly, Correa et al demonstrated a significantly higher prevalence of coronary artery abnormalities after left-breast irradiation compared with right-breast irradiation, with 70% of the abnormalities occurring in the LAD. These findings emphasize the importance of trying to avoid high radiation doses in any part of the heart, especially in the coronary arteries. Therefore, current guidelines recommend that the coronary arteries should be regarded as separate organs at risk.

The most important factor influencing the dose to the heart is the target volume. In node-negative patients undergoing radiotherapy of the breast/chest wall with tangential fields, the dose to the heart is, as a rule, low. However, it is difficult to protect the heart from irradiation when the regional lymph nodes are included in the radiation field. Irradiation of the internal mammary chain (IMC), in particular, often leads to high cardiac doses and has been demonstrated to significantly increase the rate of RIHD. Recently, two published randomized trials evaluating the benefit of IMC irradiation on overall survival demonstrated a modest survival benefit when radiotherapy in the regional nodes including the IMC was administered. A third randomized trial investigating the same research question could not reveal any survival benefit but the study was underpowered to detect such differences. Because this benefit seems to be limited and the risk for RIHD after IMC irradiation does exist, it is important to explore the benefit/risk ratio and individualize the treatment decision until further data from randomized trials are available.

Several modern radiation techniques have been introduced with the aim of reducing the radiation dose to the heart. Modern 3D conformal radiotherapy planning most often enables high target-volume coverage with estimated low radiation dose to the whole heart, but it is difficult to reduce the dose to the anterior part of the heart to non-harmful...
levels without compromising treatment effect.19 Active breathing control is a method which helps patients to reproducibly perform breath-holding during radiotherapy with the aim of delivering radiotherapy after inspiration when the heart is farthest from the irradiation. The use of active breathing control significantly reduces the dose to the whole heart and the proximal part of the LAD, but there appears to be a risk of an increase in dose in the caudal part of the LAD.23,24 Intensity-modulated radiotherapy (IMRT) has been demonstrated to further reduce the maximal dose to the heart, especially in patients with unfavorable cardiac anatomy.23 The use of volumetric modulated arc therapy, namely rotational IMRT, seems to further reduce the heart dose in patients treated with locoregional radiotherapy of left-sided breast cancer.25 Recently, the use of proton therapy (intensity-modulated proton therapy) instead of IMRT that uses photon-based radiation has been investigated in terms of heart doses. The use of intensity-modulated proton therapy significantly decreased the radiation dose to the heart and LAD compared with IMRT with breath-hold technique.26 Whether this decreased dose is clinically relevant for the patients needs to be determined in further studies.

When estimating the risk–benefit of radiotherapy in the individual patient, it is also important to consider other factors that increase the risk of RIHD, such as smoking, diabetes, or a history of ischemic heart disease.12,13 The only way of totally avoiding the risk of RIHD is to omit radiotherapy. However, as previously described, radiotherapy significantly increases breast cancer-specific survival and overall survival in most patients, but studies have demonstrated that it can be a safe to omit radiotherapy in older patients with low-risk breast cancer.27

**Chemotherapy-induced cardiac toxicity in early breast cancer**

**Anthracycline-based chemotherapy**

Anthracycline-based regimens, including epirubicin or doxorubicin, have been the cornerstone of breast cancer chemotherapy in both adjuvant and metastatic settings.28 A well-documented side effect of anthracyclines is cardiac toxicity.29 The most common manifestation of anthracycline-induced cardiotoxicity is left ventricular dysfunction that may be systolic or diastolic, asymptomatic or symptomatic. Although anthracycline-related cardiotoxicity is a well-known adverse effect, its underlying mechanism remains to a large extent unknown. The hypothesis on the role of oxygen free radicals that could lead to irreversible damage in myocardiocytes has been called into question since it does not seem to explain the whole mechanism.30 Recently, a molecular hypothesis has been proposed in which anthracycline impairs DNA repair pathways through the interaction with the topoisomerase-II-beta enzyme in myocytes.30

Anthracycline-related cardiac toxicities represent an irreversible form of chemotherapy-related cardiac dysfunction (CRCD), referred to as type I CRCD.31 This type of CRCD is different from the cardiac toxicity caused by trastuzumab which will be discussed later in this review. A recent meta-analysis revealed a 5.4-fold increased risk of clinical cardiotoxicity, 6.3-fold increased risk of subclinical cardiotoxicity, and a fivefold increased risk of cardiac death among cancer patients treated with anthracyclines compared to those treated with non-anthracycline-based regimens.32

Several risk factors have been associated with an increased risk for anthracycline-related cardiotoxicity, with the most robust to be the cumulative dose.33 For doxorubicin, the estimated percentage of patients with doxorubicin-related heart failure was found to be 5.0% at a cumulative dose of 400 mg/m², 26.0% at 550 mg/m², and 48.0% at 700 mg/m².34 Likewise for epirubicin, the risk of cardiotoxicity increased from 1.9% at doses of 800 mg/m² to 4.3% at doses of 900 mg/m² and 15.0% at doses of 1,000 mg/m².35 These observations have led to the adoption of thresholds on the accepted cumulative dose of anthracyclines in treated patients. These thresholds are differed between epirubicin and doxorubicin since, at equimolar doses, epirubicin is less cardiotoxic than doxorubicin because of the lower levels of secondary alcohol metabolites that are produced from epirubicin.36 In the previously mentioned meta-analysis, the authors found that the use of epirubicin significantly decreased the risks of both clinical and subclinical cardiotoxicity.32 However, recent evidence indicates that anthracycline-related cardiotoxicity may occur even in lower cumulative doses, especially among patients with preexisting cardiovascular risk factors, and therefore no safe threshold does exist.37 Consequently, in patients with anthracycline-based therapy, it is essential to take into account other classical risk factors for cardiac toxicity as well, such as the age at the time of drug exposure, concomitant administration of other cardiotoxic chemotherapeutic agents (trastuzumab), concurrent or prior chest irradiation, and preexisting cardiovascular disease (including coronary artery disease, hypertension, peripheral vascular disease, diabetes).37

Based on the well-recognized risk factors for anthracycline-related cardiotoxicity, a variety of approaches have been considered to decrease the risk of cardiotoxicity while maintaining efficacy. These include the limitation of the total...
cumulative dose, alterations in schedules of drug administration, modifications of the anthracycline molecule (liposomal anthracyclines), administration of non-anthracycline-based chemotherapy without jeopardizing survival, and use of adjunctive cardioprotective treatment with dexrazoxane.\(^\text{38}\)

Infusional administration of anthracyclines over 6 hours or more may lower the incidence of cardiotoxicity compared to bolus therapy. A Cochrane review of five randomized controlled trials found that continuous infusion of 6 hours or longer significantly reduced the risk of clinical heart failure (and probably also subclinical cardiac damage) when compared with infusions of 1 hour or less.\(^\text{38}\) There was no evidence that continuous infusion reduced response rate or survival. Despite these observations, the continuous infusion has several drawbacks (need for hospitalization and central venous catheters, questionable cost-effectiveness) that limit its clinical use.

Encapsulation of doxorubicin into liposomes significantly reduces its distribution volume, diminishing its diffusion and consequently, the toxicity for healthy tissues.\(^\text{39}\) In the previously mentioned meta-analysis, liposomal compared to conventional doxorubicin significantly decreased the risk of clinical and subclinical cardiotoxicity.\(^\text{32}\) However, all the studies included in the meta-analysis investigated the role of liposomal doxorubicin in patients with metastatic breast cancer. The role of liposomal doxorubicin in the adjuvant setting is still under investigation. Early Phase II trials have found that liposomal doxorubicin seems to be a feasible option for elderly patients,\(^\text{40}\) and in concurrent administration with trastuzumab\(^\text{41}\) as adjuvant treatment. Several randomized trials with the aim of investigating the efficacy and safety of liposomal doxorubicin in elderly early breast cancer populations are ongoing. Advances in the liposome formulation, with the use of cross-linked multilamellar liposome, have been recently published and showed, in vivo experiments, a reduced systemic toxicity and improved anticancer activity compared to currently used liposomal doxorubicin.\(^\text{42}\) This new formulation has the ability to incorporate two different chemotherapeutic agents into the same liposome (doxorubicin and paclitaxel) to reduce the toxicity and increase the synergistic effect.\(^\text{43}\) Further studies on this new liposome formulation are warranted.

Dexrazoxane is an iron-chelating agent that is thought to decrease the cardiotoxic effect of doxorubicin by blocking the generation of free radicals. In a meta-analysis of six randomized trials, of which only three examined dexrazoxane use in a homogenous breast cancer population receiving initial anthracycline-based therapy, dexrazoxane given with either doxorubicin or epirubicin significantly reduced the incidence of clinical and subclinical cardiotoxicity. However, there was a nonsignificant trend toward lower response rates among those who received anthracycline plus dexrazoxane.\(^\text{38}\)

Considering the lack of clinical data on dexrazoxane in the adjuvant setting and the concerns about potential impact on antitumor efficacy, dexrazoxane is not recommended for use in early breast cancer.

Finally, avoidance of anthracycline-based chemotherapy in the adjuvant setting is a certain strategy to reduce anthracycline-associated cardiotoxicity. Recently, the triplet docetaxel–carboplatin–trastuzumab was proved to be as effective as the anthracycline and taxane-based standard of care chemotherapy with less cardiac events, and it offers a valuable alternative in patients with human epidermal growth factor 2 (HER2) early breast cancer.\(^\text{44}\)

Addition of taxanes

The addition of taxanes to anthracycline-based chemotherapy as adjuvant therapy reduces the risk of recurrence and overall mortality by 4.6% and 3.2%, respectively.\(^\text{45}\) Thus, it is considered standard of care in the adjuvant setting. In early studies, concerns were raised about the higher risk for bradycardia and cardiac arrhythmias with paclitaxel\(^\text{46}\) as well as higher risk for left ventricular diastolic dysfunction with docetaxel.\(^\text{47}\) However, studies with a large number of patients did not confirm these results.\(^\text{48}\)

Paclitaxel seems to interfere with the metabolism and excretion of anthracycline metabolites that contribute to the mechanism of cardiac toxicity.\(^\text{49}\) Indeed, the combination of bolus doxorubicin and paclitaxel resulted in an unacceptably high risk of cardiac complications.\(^\text{50}\) On the contrary, the combination of epirubicin and paclitaxel was feasible with respect to cardiac toxicity as long as the cumulative dose of epirubicin did not exceed the threshold of 990 mg/m\(^2\).\(^\text{51}\)

Modern adjuvant regimens including taxanes do not increase the anthracycline cardiotoxicity as has been clearly shown in a meta-analysis of recent randomized trials.\(^\text{52}\) Conversely, taxane schemes that contain less anthracyline than control arms were associated with less cardiovascular toxicity.\(^\text{52}\)

Endocrine therapy: does it negatively affect cardiac function?

Adjuvant endocrine therapy in estrogen receptor-positive early breast cancer significantly reduces the risk of breast cancer recurrence and improves overall survival.\(^\text{53–55}\) Tamoxifen is the recommended treatment in premenopausal
women, whereas aromatase inhibitors (AI) have demonstrated superiority compared with tamoxifen in postmenopausal women.\textsuperscript{54–56} Tamoxifen is a selective estrogen receptor modulator with both antagonistic and agonistic estrogen properties. AI (anastrozole, letrozole, exemestane) exert their effect by blocking the conversion of androgens to estrogens and thereby reducing levels of estrogen in plasma and tissue.\textsuperscript{57} It has been hypothesized that this interference in the normal estrogen system could influence the risk of cardiovascular disease.

Tamoxifen has been shown to reduce plasma levels of low-density lipoprotein cholesterol, which in other circumstances has been associated with a decrease in the risk of cardiovascular events.\textsuperscript{58} In a meta-analysis evaluating tamoxifen and focusing on adverse effects, tamoxifen was associated with a decreased risk of death from myocardial infarction although no impact on the incidence of myocardial infarction was observed.\textsuperscript{59} However, in the meta-analysis by the Early Breast Cancer Trialists’ Collaboration Group, no significant reduction in cardiovascular mortality was demonstrated.\textsuperscript{33} In contrast to tamoxifen, treatment with AIs has been associated with increased levels of cholesterol,\textsuperscript{54,56} which has led to a fear of an increased risk of cardiovascular adverse events. In the pivotal trial for anastrozole, patients were randomized between anastrozole, tamoxifen, or a combination of both. No significant difference in cardiovascular deaths between the groups was observed but anastrozole treatment was associated with an increase in mild to moderate angina and hypertension.\textsuperscript{60} In another trial, 5 years of treatment with letrozole were compared with tamoxifen or sequential treatment with both substances. After a median follow-up of 51 months, patients treated with letrozole had a higher incidence of cardiac events grade 3–5, cardiac failure grade 3–5, and peripheral atherosclerotic events.\textsuperscript{61} Similar results were seen in a study evaluating tamoxifen or tamoxifen in sequence with exemestane, in which the treatment group with exemestane had significantly more ischemic cardiac adverse events after a median follow-up of 91 months.\textsuperscript{62} On the other hand, no increased risk of cardiovascular adverse events with AI could be observed in a large trial evaluating prolonged treatment with letrozole or tamoxifen after completion of 5 years tamoxifen treatment.\textsuperscript{63}

In summary, AI seem to entail a minor increase in the risk of cardiac adverse events whereas tamoxifen does not seem to entail any cardiac risks. In most patients, this potential risk of cardiovascular adverse events with AI is outweighed by the treatment’s significant improvement in breast cancer survival. When choosing treatment for the individual patient, it is also important to consider other side effects of the different treatments; these have been discussed elsewhere.\textsuperscript{53–56}

**Anti-HER2-induced cardiac toxicity**

Trastuzumab, a humanized anti-HER2 monoclonal antibody, is the standard of care in patients with HER2-positive breast cancer in any treatment setting. The importance of trastuzumab in HER2-positive breast cancer disease was first demonstrated in the metastatic setting, in which trastuzumab changed the natural history of HER2-positive disease from a clinical entity with poor prognosis (patients with HER2-positive breast cancer had the worst prognosis among breast cancer patients) to a disease with comparable or even better outcome than HER2-negative disease.\textsuperscript{64} In the adjuvant setting, 1-year treatment with trastuzumab offers substantial benefit in terms of both disease-free and overall survival.\textsuperscript{65} Trastuzumab was first approved in 1998 for the treatment of HER2-positive metastatic breast cancer, and cardiac dysfunction was recognized early on as a potential toxicity of trastuzumab.\textsuperscript{66} In the early pivotal trials in the metastatic setting, the rates of cardiac dysfunction ranged from 8% to the unacceptably high rate of 30% in cases of concomitant administration of trastuzumab with anthracyclines.\textsuperscript{66} These findings had a major impact on the design of adjuvant trials in which strict cardiac exclusion criteria, prospective monitoring of cardiac function, interim cardiac safety analyses, as well as treatment schedules with sequential use of anthracyclines and trastuzumab instead of concomitant administration were adopted.\textsuperscript{67} As a result, the cardiotoxicity rates in adjuvant randomized trials were lower than in metastatic ones (symptomatic congestive heart failure rate ranged between 0.8% and 14.2%).\textsuperscript{67} However, a significantly increased risk for both left ventricular ejection fraction (LVEF) decline and congestive heart failure was observed in the trastuzumab-treated arm.\textsuperscript{68} In the real-world setting, where the cardiac exclusion criteria are not as strict as those applied in the randomized controlled trials, the rate of cardiac toxicity is similar to the one observed in randomized clinical trials.\textsuperscript{69,70}

The pathophysiological mechanisms underlying trastuzumab-related cardiotoxicity are not completely clear. Preclinical data have suggested an important role for the HER2 signaling pathways in cardiac physiology, given that both HER receptors and their ligands are expressed in the cardiomyocytes.\textsuperscript{71} The mechanisms of trastuzumab-induced cardiotoxicity differ substantially from those of anthracyclines. Trastuzumab-induced cardiotoxicity, as opposed to anthracycline-induced cardiotoxicity, is not dose dependent, is reversible upon therapy withdrawal,
and the drug can be safely readministered after recovery of cardiac function.\(^3\) The cardiac toxicity due to trastuzumab is classified as type II CRCD.\(^3\) One potential mechanism of cardiotoxicity is the inactivation of a HER ligand-mediated pathway that leads to cell survival in case of adverse hemodynamics or other stress.\(^7\) This proposed mechanism could explain both the higher risk for cardiotoxicity when trastuzumab and anthracyclines are combined (the stress and damage caused by anthracyclines is increased) and the reversibility of cardiotoxicity with trastuzumab withdrawal (the pathway is becoming functional again).\(^7\)

Several risk factors for trastuzumab-induced cardiotoxicity have been identified.\(^6\) The most important one is the concomitant administration with anthracyclines. It has been demonstrated that there is a clear effect of cumulative anthracycline dose and trastuzumab-induced cardiotoxicity.\(^7\)\(^-\)\(^7\)\(^5\) On the contrary, in the neoadjuvant setting, the concomitant administration of anthracyclines and trastuzumab, compared with sequential administration, was not correlated with higher risk for cardiac adverse events.\(^7\)\(^6\)\(^-\)\(^7\)\(^8\) However, in the absence of any difference in the pathologic complete remission with the concurrent administration of trastuzumab and epirubicin,\(^7\)\(^8\) and considering the concerns about the limited follow-up for cardiac events in these studies,\(^7\)\(^6\) this approach is not recommended as standard of care.

Advanced age has also been associated with an increased risk of trastuzumab-induced cardiotoxicity.\(^7\)\(^4\)\(^-\)\(^7\)\(^9\) Older patients appear to face a higher risk for cardiac toxicity due to trastuzumab, with higher rates than those reported in randomized clinical trials.\(^8\)\(^9\) Other potential risk factors are antihypertensive medications,\(^7\)\(^9\) borderline cardiac function at baseline,\(^7\)\(^9\) and a history of heart disease.\(^8\)\(^1\)

Some efforts have been made to identify certain polymorphisms in the HER2 gene that could trigger cardiotoxicity. The polymorphism I655V in the HER2 gene has been associated with cardiac toxicity in three different research groups.\(^8\)\(^2\)\(^-\)\(^8\)\(^4\) As our knowledge about the mechanism of trastuzumab-induced cardiotoxicity increases, and with the help of genome-wide association studies, it is possible that pharmacogenomics will play an important role in the near future as an approach to identify patients at high risk for trastuzumab-induced cardiac toxicity.

Besides trastuzumab, two additional anti-HER2 agents have been developed and approved for the treatment of HER2-positive breast cancer: the tyrosine kinase inhibitor lapatinib is approved in metastatic setting\(^6\)\(^5\) and the monoclonal antibody pertuzumab is approved in the neoadjuvant and metastatic setting.\(^8\)\(^6\)\(^-\)\(^8\)\(^7\) Recently, a new treatment option for HER2-positive breast cancers consisting of the combination of two anti-HER2 agents has been evaluated. Lapatinib in combination with trastuzumab has shown promising results as neoadjuvant\(^8\)\(^9\) and metastatic treatment.\(^8\)\(^9\) while pertuzumab has been approved only in combination with trastuzumab both as neoadjuvant and as metastatic treatment. Those two anti-HER2 agents have also been associated with cardiac toxicity.\(^8\)\(^5\)\(^-\)\(^8\)\(^7\) There is, therefore, a concern regarding the potential risk for increased cardiac adverse events when two anti-HER2 agents that both increase cardiac toxicity are combined. However, a recent meta-analysis could not reveal any increased risk for cardiac toxicity with any of the combinations compared with monotherapy with one anti-HER2 agent.\(^9\)\(^0\) Several randomized trials investigating the role of dual anti-HER2 blockade in the adjuvant setting are ongoing.

### Assessment and monitoring of cardiac health in breast cancer patients with adjuvant therapy

There are several recommendations and guidelines available for the assessment and monitoring of cardiac toxicity during and after breast cancer treatment.\(^9\)\(^1\)\(^-\)\(^9\)\(^5\) These recommendations are mainly based on expert consensus due to the paucity of available high-level evidence.

Two of the basic concepts that are common in all the guidelines are: the value of a careful case-by-case baseline evaluation of preexisting risk factors for cardiac adverse events and the need for an appropriate and well-structured cardiac monitoring during and after cancer therapy to identify patients with asymptomatic cardiac dysfunction, so that breast cancer treatments can be modified and cardiac medication can be started.

Table 1 presents a summary of recommendations and areas of active research regarding assessment, monitoring, and treatment of cardiac toxicity due to cancer therapy in patients with early breast cancer.

### Baseline assessment/evaluation

The purpose of the baseline evaluation is to identify patients with high risk for cardiac toxicity due to cancer therapy. We discussed earlier in the review that several risk factors for cardiac toxicity during anticancer therapy have been identified. However, it is difficult to incorporate the baseline assessment in an algorithm for cardiac monitoring because of the lack of evidence about the strength of each risk factor in the estimation of cardiac risk. The only available cardiac risk score has been developed by investigators from the
Table 1 Assessment, monitoring, and management of cardiac toxicity due to breast cancer treatment

<table>
<thead>
<tr>
<th>Cancer treatment</th>
<th>Assessment/monitoring</th>
<th>Prevention</th>
<th>Under investigation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiotherapy</td>
<td>Conventional imaging technique at baseline&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Modern RT techniques to minimize heart dose (3D conformal RT, IMRT, ABC)</td>
<td>Statins</td>
</tr>
<tr>
<td></td>
<td>Conventional imaging as monitoring at 10 years after radiotherapy (at 5 years in high-risk patients) and then every 5 years&lt;sup&gt;9&lt;/sup&gt;</td>
<td></td>
<td>ACE-i/ARB</td>
</tr>
<tr>
<td></td>
<td>Baseline evaluation of risk factors&lt;sup&gt;9,91&lt;/sup&gt;</td>
<td></td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>Adequate management of cardiovascular risk factors&lt;sup&gt;9,91&lt;/sup&gt;</td>
<td></td>
<td>Diuretics (symptomatic heart failure)</td>
</tr>
<tr>
<td></td>
<td>Serum cardiac biomarkers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D echocardiography</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiac MRI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anthracyclines</td>
<td>Conventional imaging technique at baseline&lt;sup&gt;9,92&lt;/sup&gt;</td>
<td>Approaches to reduce risk for anthracycline-induced cardiotoxicity (avoid excess cumulative dose, prefer infusion instead of bolus, use of non-anthracycline-based chemotherapy)</td>
<td>ACE-i/ARB</td>
</tr>
<tr>
<td></td>
<td>Conventional imaging as monitoring (3, 6, 9, 12, 18 months&lt;sup&gt;7&lt;/sup&gt; or at the completion of treatment and 6 months later&lt;sup&gt;92&lt;/sup&gt;)</td>
<td></td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>Baseline evaluation of risk factors&lt;sup&gt;9,92&lt;/sup&gt;</td>
<td></td>
<td>Diuretics (symptomatic heart failure)</td>
</tr>
<tr>
<td></td>
<td>Adequate management of cardiovascular risk factors&lt;sup&gt;9,92&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Serum cardiac biomarkers (troponin&lt;sup&gt;92&lt;/sup&gt; or troponin plus BNP&lt;sup&gt;91&lt;/sup&gt;) may be useful at baseline and for monitoring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3D echocardiography</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiac MRI</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Serum cardiac biomarkers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Conventional imaging technique at baseline&lt;sup&gt;9,92&lt;/sup&gt;</td>
<td>Approaches to reduce risk for anthracycline-induced cardiotoxicity (use of liposomally encapsulated anthracyclines in adjuvant setting)</td>
<td>ACE-i/ARB</td>
</tr>
<tr>
<td></td>
<td>Conventional imaging as monitoring (3, 6, 9, 12, 18 months&lt;sup&gt;91&lt;/sup&gt; or every 3 months during therapy and 6 months later for those who had previously received anthracyclines&lt;sup&gt;92&lt;/sup&gt;)</td>
<td></td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>Baseline evaluation of risk factors</td>
<td></td>
<td>ACE-i/ARB</td>
</tr>
<tr>
<td></td>
<td>Adequate management of cardiovascular risk factors</td>
<td></td>
<td>Aerobic exercise</td>
</tr>
<tr>
<td></td>
<td>Serum cardiac biomarkers (troponin&lt;sup&gt;92&lt;/sup&gt; or troponin plus BNP&lt;sup&gt;91&lt;/sup&gt;) may be useful at baseline and for monitoring</td>
<td></td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>3D echocardiography</td>
<td></td>
<td>ACE-i/ARB</td>
</tr>
<tr>
<td></td>
<td>Cardiac MRI</td>
<td></td>
<td>Beta-blockers</td>
</tr>
<tr>
<td></td>
<td>Serum cardiac biomarkers</td>
<td></td>
<td>Diuretics (symptomatic heart failure)</td>
</tr>
</tbody>
</table>

Note: The recommendations are based on guidelines from ESMO<sup>91</sup> and American Society of Echocardiography/European Association of Cardiovascular Imaging<sup>92</sup> guidelines.

Abbreviations: ABC, active breathing control; ACE-i, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BNP, B-type natriuretic peptide; IMRT, intensity-modulated radiotherapy; MRI, magnetic resonance imaging; RT, radiotherapy; TDI, tissue Doppler imaging.
NSABP B-31 trial (trastuzumab versus no trastuzumab in the adjuvant setting) to predict the absolute risk of heart failure in individual patients who received trastuzumab as adjuvant therapy. However, the lack of independent validation of the model limits its clinical use so far.

The baseline evaluation also includes a cardiac imaging test for the evaluation of cardiac structure and function. Some guidelines recognize the practical difficulty to perform baseline imaging evaluation on all the patients with breast cancer before adjuvant treatment and recommend evaluation only for women with risk factors for cardiac toxicities or those who are planned to receive high cumulative doses of anthracyclines or at least two therapies that could influence heart function. However, baseline imaging is mandatory for all the patients who are planned to receive trastuzumab without any exceptions.

At present, the most frequently used modality for detecting cardiotoxicity is the measurement of LVEF by using either echocardiography or multigated acquisition scanning (MUGA). Echocardiography is generally preferred over MUGA due to its widespread availability, the ability to investigate the diastolic function as well, and the absence of radiation exposure. However, echocardiography is dependent on expertise and interpretation of echocardiographers while MUGA offers a more objective and reliable calculation of LVEF.

The major shortcoming in measuring LVEF is that it is insensitive to slight changes in myocardial function. As a consequence, the decrease in LVEF occurs when a critical amount of myocardial damage, which might be irreversible, has already occurred. Moreover, LVEF is a measurement of systolic cardiac function and it does not provide any assessment of other measurements such as diastolic function or valvular structure and function.

Novel ultrasound imaging techniques including tissue Doppler imaging (TDI) and 3D and contrast echocardiography could overcome some of the shortcomings of conventional echocardiography. Contrast and 3D echocardiography offer a more accurate calculation of LVEF compared with standard 2D echocardiography. In addition, 3D echocardiography might provide a tool for earlier identification of subclinical myocardial damages. TDI is a relatively new echocardiographic technique that uses Doppler principles to measure the velocity of myocardial motion, deformation (strain), and rate of deformation (strain rate). Clinical studies have found that TDI measurements are able to detect preclinical changes in systolic function before conventional changes in LVEF, irrespective of the cancer therapy (anthracyclines, radiotherapy, trastuzumab) that was responsible for the cardiac toxicity. Recently, studies on the general population found that the coronary artery score, by using computed tomography, could serve as an additional marker for the prediction of coronary artery disease. Whether this marker can be used in the baseline assessment of patients with breast cancer before adjuvant therapy is unknown. Further studies are necessary to identify the predictive value of these imaging modalities.

Cardiac magnetic resonance imaging is considered the gold standard for LVEF assessment and volume and mass measurements. Early studies in cancer patients allowed accurate identification of subclinical or established cardiotoxicity from cancer therapy. However, its lack of availability and high cost limit its routine use. In a recent review, the authors concluded that based on the current data of cost and availability of the method, magnetic resonance imaging seems to be an important complement to the current algorithms of cardiac assessment and monitoring rather than a screening tool for all the patients treated with cardiotoxic cancer therapy.

Besides imaging modalities, a new approach based on biochemical cardiac markers (troponins T and I, B-type natriuretic peptide [BNP], N-terminal pro-BNP [NT-proBNP]) has emerged as a tool for both baseline assessment and monitoring during cancer therapy. In patients treated with anthracyclines, an early elevation of troponin seems to identify patients at risk for cardiac toxicity which allows the individualization of monitoring and the adoption of preventive strategies in selected patients. Similarly, in patients treated with trastuzumab, elevation of troponin during therapy could identify a group of patients at high risk for cardiac toxicity and with a lower likelihood of recovery of cardiac function. However, others have failed to detect any clinical value of cardiac troponins during or following cancer therapy.

The family of natriuretic peptides (BNP, NT-proBNP) has also been investigated as markers of early cardiac damage during cancer therapy with less reliable and consistent results than troponin. Some studies have found an association between elevation of BNP or NT-proBNP and higher risk for cardiac toxicity while others did not find any correlation at all.

There are a number of barriers in cardiac biomarker studies that limit their widespread application as early markers of cancer therapy-induced cardiac toxicity. First, the timing of biomarker assessment varied among studies, which may in part explain the inconsistent results, and the optimal timing remains unanswered. Moreover, the optimal assay as well as
a widely acceptable cut-off value is still to be determined. In addition, most of the available studies are small with heterogeneous cancer populations who received multiple types of cancer therapy. As a result, the utility of cardiac biomarkers as diagnostic and predictive tools for cardiac dysfunction in patients with potential cardiotoxic cancer therapy remains to be clarified when results from larger ongoing studies are available. Despite these caveats, some guidelines have already included the measurements of cardiac biomarkers in their suggested algorithms.91,92

Guidelines on cardiac monitoring
The same imaging modalities and cardiac biomarkers that were discussed earlier as methods for baseline assessment and evaluation are also available as methods for cardiac monitoring during cancer therapy. Echocardiography or MUGA for the calculation of LVEF is the current backbone to all the current guidelines regarding cardiac monitoring during cancer therapy.9,91–95

The ESMO guidelines recommend serial monitoring of cardiac function with echocardiography or MUGA at baseline; at 3, 6, and 9 months during treatment (anthracyclines and/or trastuzumab); and then at 12 and 18 months after the initiation of treatment.91 The authors discuss also the possibility of the use of repeated measurements of cardiac biomarkers as an additional monitoring.91 However, they recognize the need for further data by classifying this recommendation as B, with a level of evidence III. There are no recommendations about the assessment and monitoring of breast cancer patients treated with radiotherapy in the ESMO guidelines.91

The guidelines from the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI) are largely similar to the ESMO guidelines concerning the time intervals in cardiac monitoring during trastuzumab therapy and the potential value of cardiac biomarkers in the baseline assessment and monitoring.92 However, there are some differences in some recommendations: the ASE/EACVI guidelines recommend cardiac monitoring 6 months after completion of trastuzumab therapy only in patients who had previously received a type I cardiotoxic agent (ie, anthracyclines); besides cardiac biomarkers, the ASE/EACVI guidelines recommend (with the same grade of recommendation) the use of an additional echocardiographic parameter, namely global longitudinal strain; and the ASE/EACVI guidelines recommend that the cardiac monitoring during anthracycline-based chemotherapy will be at baseline, at the completion, and 6 months after the completion of the treatment.

The same societies (ASE/EACVI) currently released the first guidelines about assessment and cardiac monitoring in adult patients with cancer treated with radiotherapy that will result in a radiation dose to the heart.9 The authors recommend baseline assessment of cardiovascular risk factors and baseline echocardiography to identify any cardiac abnormalities for all the patients before radiotherapy. During follow-up, a yearly history and physical examination with close attention to symptoms and signs of heart disease is recommended. In asymptomatic patients, screening echocardiography is recommended 10 years after treatment (or 5 years in case of high-risk populations, namely those who received left-side chest radiotherapy or those with at least one risk factor for RHID) and then every 5 years after the initial 10-year echocardiographic screening examination. In the high-risk population, noninvasive stress imaging to screen for coronary artery disease should be considered due to the increased risk of coronary events 5–10 years after radiotherapy.9

Prevention and management of cardiac toxicity in breast cancer survivors

Strategies to prevent cardiac toxicity
There is a growing interest in the use of standard cardiovascular medications to prevent cardiac toxicity due to cancer therapy in breast cancer patients. HMG-CoA reductase inhibitors (statins) have been shown to attenuate doxorubicin-induced cardiomyocyte cell death122 and radiation-induced cell apoptosis123 in preclinical studies. One retrospective study (201 patients)124 and one small randomized trial (40 patients)125 support the potential role of statins in reducing heart failure and maintaining cardiac function in breast cancer patients treated with anthracyclines. No clinical data on the potential protective effect of statins in radiation-induced cardiac toxicity are available. Several studies that investigate the use of statins to prevent cancer therapy-associated cardiac toxicity in breast cancer patients are ongoing and the results will enlighten their role as cardioprotective agents.

Beta-blockers have also been studied as preventive agents against cardiac toxicity in breast cancer patients. Although the exact mechanism of cardioprotection with beta-blockers remains to be determined, several mechanisms have been proposed based on preclinical data including mitigation of oxidative stress126 and preservation of b-adrenergic receptor recruitment of b-arrestin, which is an endogenous protective agent.127 In the only published randomized trial dedicated to patients with breast cancer, the administration of nebivolol
(n=27) under anthracycline-based chemotherapy was associated with lower risk for LVEF decline at 6 months compared to the placebo arm (n=18). Similar data were observed in two additional randomized trials: a small trial with 50 patients treated with anthracycline-based chemotherapy (34 of 50 patients had breast cancer) in which carvedilol was compared to placebo, and a larger trial including 90 patients with hematologic malignancies in which the combination of enalapril and carvedilol was compared to nonintervention. This latter trial (OVERCOME trial) is the first randomized trial investigating the protective effect of cardiovascular medication in cancer treatment-related cardiotoxicity that presented not only data on surrogate outcomes of cardiac toxicity, but also clinically relevant outcomes such as symptomatic heart failure and death. Interestingly, patients in the intervention group had a lower incidence of the combined event of death or heart failure in comparison with nonintervention group. In contrast with beta-blockers and anthracycline-based cardiotoxicity, there is scarce clinical evidence about the role of beta-blockers and angiotensin-converting enzyme inhibitors (ACE-i) to higher possibility for LVEF recovery. As we pointed out for the statins, several randomized trials are ongoing and will hopefully give a definitive answer to the question of the role of beta-blockers as cardioprotective agents in anthracycline- and trastuzumab-associated cardiac toxicity.

The third category of cardiovascular medication with potential benefit as a cardioprotective agent for cancer therapy-related cardiotoxicity is ACE-i/angiotensin II receptor blockers (ARB). Several mechanisms that could mediate this cardioprotective effect have been proposed based on preclinical data: reduction in interstitial fibrosis, attenuation of oxidative stress, and downregulation of the actions of the NRG-1/ErbB system. Several small randomized trials have found that the administration of ACE-i/ARB during anthracycline-based chemotherapy reduces the risk for cardiac dysfunction as it is measured by conventional cardiac imaging modalities. In addition, the previous mentioned OVERCOME trial, the combination of beta-blockers and ACE-i resulted in lower risk for clinically relevant outcomes as well. The study of Cardinale et al is unique in its design since the authors used a biomarker (troponin I) to guide treatment. The authors used the elevation of troponin I which was measured soon after high-dose chemotherapy to select 114 patients with various malignancies for randomization to placebo versus enalapril 20 mg daily for 1 year. The incidence of LVEF decline ≥10% was significantly higher in the control (43%) than in the ACE-i treated arm (0%). There is only preclinical data; there is no clinical evidence on the potential cardioprotective effect of ACE-i/ARB under trastuzumab or radiation therapy. However, this potential cardioprotective effect is an area of active investigation.

Besides the pharmacological interventions, some preclinical data suggest that even nonpharmacological interventions may have an impact in the prevention of cardiac toxicity. It has been found that aerobic exercise attenuates doxorubicin-induced cardiotoxicity in animal models. However, a small study in patients treated with trastuzumab found that the exercise training was not effective in preventing adverse left ventricular remodeling. Whether the aerobic exercise is a protective intervention against anthracycline- or trastuzumab-related cardiac toxicity in breast cancer patients needs to be studied in further randomized trials.

The only medication that has been approved by the US Food and Drug Administration for the prevention of anthracycline-related cardiotoxicity is dexrazoxane. Its mechanism of action and clinical evidence for its use was described earlier in this review. It is basically not in use in clinical practice due to concerns about the potential negative impact on antitumoral activity of anthracyclines.

Management of cardiac toxicity

In the general population, the guidelines suggest the use of beta-blocker and ACE-i/ARB in patients with asymptomatic LVEF decline. It is generally accepted that a similar treatment strategy, namely the initiation of appropriate medication promptly after the detection of asymptomatic cardiac dysfunction, should be obtained in patients with cardiac dysfunction due to cancer therapy as well. However, the evidence behind this treatment strategy for cancer patients is coming from relatively small prospective studies and further studies, preferably randomized trials, are still needed. In trastuzumab-treated patients, the evidence that supports the use of ACE-i/ARB with or without beta-blockers in asymptomatic cardiac dysfunction (LVEF <40% or between 40% and 50% in some guidelines) is limited to small case series, but this strategy is generally accepted. Two additional parameters that should be taken into account in trastuzumab-induced cardiac toxicity are the need to withhold trastuzumab according to specific criteria (LVEF ≤44, or LVEF 45–49 and ≥10 from baseline) with reevaluation after 3–4 weeks and the fact that the therapeutic target with cardiovascular medications should be achieved.
faster than in the general population in order to readminister trastuzumab. 146

In cases of symptomatic heart failure due to cancer therapy, the recommended treatment strategy does not differ from the treatment of heart failure patients in general91 and includes routine use of ACE-i or ARB and beta-blockers with diuretics added for symptomatic congestion. In trastuzumab-induced heart failure, LVEF should be reevaluated after adequate dose titration of cardiovascular medication and, if it returns to baseline, trastuzumab can be restarted in combination with cardiovascular medications. 91,144 If LVEF stays persistently low or further declines, or in case of recurrence of heart failure symptoms, the treating oncologist should discuss with the patient the risk and benefit of discontinuation of trastuzumab. 91,144 Patients with radiation-induced heart diseases should be treated as non-radiation-related patients. 91

Conclusion

Adjuvant treatment with radiotherapy, anthracycline-based chemotherapy, and/or trastuzumab are important parts of postoperative therapy for many women with early breast cancer. These treatment strategies are associated with cardiac adverse events through different pathophysiological mechanisms. Several guidelines recommend initial baseline assessment and appropriate cardiac monitoring to reveal cardiac dysfunction at an early stage of cancer therapy. However, several important issues remain unresolved including the optimal timing of assessment; monitoring and initiation of cardiovascular medication; the role of modern imaging modalities as well as the role of cardiac biomarkers as early predictors of cardiac toxicity; the potential role of cardiovascular medications as cardioprotective agents; and the value of new radiotherapy techniques in reducing long-term cardiotoxicity. These issues are the focus of ongoing research. An extensive collaboration between cardiologists and oncologists in the fields of both scientific research and clinical practice is essential to further develop and implement adequate cardioprotective strategies for patients with early breast cancer.

Disclosure

The authors report no conflict of interest in this work.

References


Breast Cancer: Targets and Therapy 2015:7


73. Farolfi A, Melegari E, Aquilina M, et al. Trastuzumab-induced cardio

72. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the

events during adjuvant endocrine therapy for early breast cancer using

70. Naumann D, Rusius V, Margiotta C, et al. Factors predicting trastuzumab-


68. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing

67. Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associ-
ated with adjuvant trastuzumab therapy: prevalence, patient character-

66. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the

65. Viani GA, Afonzo SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant
trastuzumab in the treatment of her-2 positive early breast cancer: a meta-

64. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH.

63. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole fol-
lowing tamoxifen as extended adjuvant therapy in receptor-positive

long-term follow-up: an updated analysis of the intergroup exemestane

events during adjuvant endocrine therapy for early breast cancer using

60. Arimided, Tamoxifen, Alone or in Combination Trialists’ Group, Buzdar A, Howell A. Comprehensive side-effect profile of anas
trozole and tamoxifen as adjuvant treatment for early-stage breast

78. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epiru-
ubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus
trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75
plus trastuzumab as neoadjuvant treatment for patients with HER2-
positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.

77. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of dox-
orubicin and cyclophosphamide followed by paclitaxel with or without
trastuzumab in the North Central Cancer Treatment Group N9831

76. Chen J, Long JB, Hurria A, Owsu C, Steingart RM, Gross CP. Incidence
of heart failure or cardiomyopathy after adjuvant trastuzumab therapy

cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann

gene polymorphism in tumorigenesis and in the risk of trastuzumab-

73. Lemieux J, Diorio C, Côté MA, et al. Alcohol and HER2 polymorphisms
as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.

FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity
and efficacy in a subgroup of patients from UNICANCER-PACS 04

2006;355:2733–2743.


69. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoad-
juvant pertuzumab and trastuzumab in women with locally advanced,
inflammatory, or early HER2-positive breast cancer (NeoSphere): a
randomised multicentre, open-label, phase 2 trial. Lancet Oncol.

68. Valachis A, Nearchou A, Lind P, Mauri D. Lapatinib, trastuzumab or the
combination added to preoperative chemotherapy for breast cancer: a

benefit with lapatinib in combination with trastuzumab for patients
with human epidermal growth factor receptor 2-positive metastatic

66. Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiac toxicity in
breast cancer patients treated with dual HER2 blockade. Int J Cancer.
2013;133(9):2245–2252.

induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:
vii155–vii166.

64. Piana J, Calderisi M, Barac A, et al. Expert consensus for multi-
modality imaging evaluation of adult patients during and after cancer
therapy: a report from the American Society of Echocardiography and
the European Association of Cardiovascular Imaging. Eur Heart J

63. Floyd J, Morgan JP. Cardiotoxicity of anthracycline-like chemotherapy
agents. In: UpToDate, Ross ME (Ed), UpToDate, Waltham, MA.

62. Perez EA, Morgan JP. Cardiotoxicity of trastuzumab and other HER2-
targeted agents. In: UpToDate, Ross ME (Ed), UpToDate, Waltham, MA.
(Accessed on September 14, 2015).

61. Marks LB, Contini LS, Jacob Adams M. Cardiotoxicity of radiation
therapy for malignancy. In: UpToDate, Ross ME (Ed), UpToDate,
Waltham, MA. (Accessed on September 1, 2014).

60. Arimided, Tamoxifen, Alone or in Combination Trialists’ Group, Buzdar A, Howell A. Comprehensive side-effect profile of anas-
trozole and tamoxifen as adjuvant treatment for early-stage breast


100. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2008;26(8):1201–1203.


